CLINICAL TRIALS PROFILE FOR PNEUMOCOCCAL VACCINE POLYVALENT

All Clinical Trials for pneumococcal vaccine polyvalent

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002392 ↗	A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART	Completed	Rockefeller University	N/A	1969-12-31	To ascertain the effect of thalidomide on immune responses to vaccination with polyvalent pneumococcal polysaccharide vaccine and tetanus toxoid in HIV-infected patients; particularly, on markers of immune activation and parameters of specific, anti-HIV cellular immunity.
NCT00034086 ↗	Study of Anti-HIV Therapy Intensification	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	The purpose of this study is to see how the body's immune system changes after replacing and adding new anti-HIV drugs to a patient's current anti-HIV therapy. This study will also see whether adding drugs is safe. Patients who take part in A5136 are also eligible to take part in 2 substudies. The purpose of substudy A5140s is to see how many latently infected cells (cells in which the HIV virus survives) are in the lymph node (small, rounded structures that make disease-fighting cells). Substudy A5155s will be performed to see how many latently infected cells are in the blood before and after replacing and adding anti-HIV drugs. ACTG A5136 is a follow-up study to ACTG 315 and ACTG 375, which were designed to examine the effects of highly active antiretroviral therapy (HAART) in certain HIV-infected patients. Many HIV-infected patients have undergone long-term anti-HIV therapy and have had the virus suppressed. However, most of these patients still have problems with their immune systems. The reason for these problems is unknown. This study may help researchers understand what causes immune system problems in people who have low levels of HIV in their blood.
NCT00445484 ↗	Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma	Completed	National Cancer Institute (NCI)	Phase 2	2007-01-01	RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Vaccines may help the body build an effective immune response to kill cancer cells. Giving lenalidomide together with vaccine therapy may make a stronger immune response and kill more cancer cells. PURPOSE: This phase II trial is studying how well giving lenalidomide together with vaccine therapy works in treating patients with relapsed or refractory multiple myeloma.
NCT00445484 ↗	Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma	Completed	Sidney Kimmel Comprehensive Cancer Center	Phase 2	2007-01-01	RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Vaccines may help the body build an effective immune response to kill cancer cells. Giving lenalidomide together with vaccine therapy may make a stronger immune response and kill more cancer cells. PURPOSE: This phase II trial is studying how well giving lenalidomide together with vaccine therapy works in treating patients with relapsed or refractory multiple myeloma.
NCT00445484 ↗	Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma	Completed	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 2	2007-01-01	RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Vaccines may help the body build an effective immune response to kill cancer cells. Giving lenalidomide together with vaccine therapy may make a stronger immune response and kill more cancer cells. PURPOSE: This phase II trial is studying how well giving lenalidomide together with vaccine therapy works in treating patients with relapsed or refractory multiple myeloma.

Clinical Trial Conditions for pneumococcal vaccine polyvalent

Condition Name

Condition Name for pneumococcal vaccine polyvalent
Intervention	Trials
HIV Infections	2
Multiple Myeloma and Plasma Cell Neoplasm	2
Ann Arbor Stage I Small Lymphocytic Lymphoma	1
Stage I Small Lymphocytic Lymphoma	1

Condition MeSH

Condition MeSH for pneumococcal vaccine polyvalent
Intervention	Trials
Multiple Myeloma	2
HIV Infections	2
Plasmacytoma	2
Neoplasms, Plasma Cell	2

Clinical Trial Locations for pneumococcal vaccine polyvalent

Trials by Country

Trials by Country for pneumococcal vaccine polyvalent
Location	Trials
United States	20

Trials by US State

Trials by US State for pneumococcal vaccine polyvalent
Location	Trials
Ohio	3
Maryland	2
Illinois	2
New York	2
Michigan	1

Clinical Trial Progress for pneumococcal vaccine polyvalent

Clinical Trial Phase

Clinical Trial Phase for pneumococcal vaccine polyvalent
Clinical Trial Phase	Trials
Phase 2	2
Phase 1/Phase 2	2
N/A	2

Clinical Trial Status

Clinical Trial Status for pneumococcal vaccine polyvalent
Clinical Trial Phase	Trials
Completed	5
Active, not recruiting	1

Clinical Trial Sponsors for pneumococcal vaccine polyvalent

Sponsor Name

Sponsor Name for pneumococcal vaccine polyvalent
Sponsor	Trials
National Cancer Institute (NCI)	3
Sidney Kimmel Comprehensive Cancer Center	2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	2

Sponsor Type

Sponsor Type for pneumococcal vaccine polyvalent
Sponsor	Trials
Other	5
NIH	4
Industry	1